Pharminent

Provisional NICE recommendation for Gilead’s Hepatitis C treatment

NICE has issued provisional guidance recommending the use of Gilead Sciences’ Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg) for the treatment of adult chronic hepatitis C genotype 1-6 patients in England and Wales.
This is the third sofosbuvir-based treatment to be recommended by NICE for treatment of the disease. Hepatitis C, if untreated, can cause serious liver damage and potentially life-threatening complications such as liver cancer.
read more http://www.pharmafile.com/news/509122/provisional-nice-recommendation-gilead-s-hepatitis-c-treatment

Filed under: HCV